These three biomarkers have been expanded upon in some technologies in the use of antibody cocktails including, for example, the human epidermal growth factor 2 (HER2) for breast cancer and the prostate-specific membrane antigen (PSMA) for prostate cancer. Here, FOLH1 is linked to breast carcinoma.